专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

US06753318B1 6,11-4-carbon bridged erythromycin derivatives 有权
标题翻译： 6,11-4碳桥联红霉素衍生物
公开(公告)号：US06753318B1
公开(公告)日：2004-06-22
申请号：US10205357
申请日：2002-07-25
申请人： Yat Sun Or , Guoqiang Wang , Deqiang Niu , Ly Tam Phan
发明人： Yat Sun Or , Guoqiang Wang , Deqiang Niu , Ly Tam Phan
IPC分类号： A61K3170
CPC分类号： C07H17/08
摘要： Novel 6,11-4-carbon bridged erythromycin derivatives and pharmaceutically-acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically-acceptable carrier are described. Also described are methods for treating bacterial infections by administering to an animal a pharmaceutical composition containing a therapeutically effective amount of a compound of the invention and processes for the preparation of such compounds.
摘要翻译：描述了新颖的6,11-4-碳桥连红霉素衍生物和药学上可接受的组合物，其包含治疗有效量的本发明化合物与药学上可接受的载体的组合。还描述了通过向动物施用含有治疗有效量的本发明化合物和制备这些化合物的方法的药物组合物来治疗细菌感染的方法。

62. 发明授权

US08809264B2 Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors 有权
标题翻译：喹喔啉基大环丙型肝炎病毒丝氨酸蛋白酶抑制剂
公开(公告)号：US08809264B2
公开(公告)日：2014-08-19
申请号：US11768723
申请日：2007-06-26
申请人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/00 , C07D245/04 , A61K38/21 , C07D403/12
CPC分类号： C07D245/04 , A61K38/212 , A61K38/215 , C07D403/12 , A61K2300/00
摘要： The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

63. 发明授权

US08796255B2 Mutant-selective EGFR inhibitors and uses thereof 有权
标题翻译：突变选择性EGFR抑制剂及其用途
公开(公告)号：US08796255B2
公开(公告)日：2014-08-05
申请号：US13291706
申请日：2011-11-08
申请人： Kwangho Lee , Deqiang Niu , Matthew F. Baevsky
发明人： Kwangho Lee , Deqiang Niu , Matthew F. Baevsky
IPC分类号： A61K31/495 , A61K31/505 , C07D239/02
CPC分类号： C07D403/12 , A61K31/155 , A61K31/505 , A61K31/506 , A61K45/06 , C07D239/42 , C07D239/47 , C07D239/48 , C12N9/12 , C12Y207/10 , A61K2300/00
摘要： The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
摘要翻译：本发明提供化合物，其药学上可接受的组合物及其使用方法。

64. 发明授权

US08268777B2 Oximyl macrocyclic derivatives 有权
标题翻译：甲氧基大环衍生物
公开(公告)号：US08268777B2
公开(公告)日：2012-09-18
申请号：US12327453
申请日：2008-12-03
申请人： Ying Sun , Deqiang Niu , Guoyou Xu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Deqiang Niu , Guoyou Xu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/00
CPC分类号： C07D245/04
摘要： The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
摘要翻译：本发明涉及式I化合物或其药学上可接受的盐，酯或前体药物：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

65. 发明授权

US08268776B2 Macrocylic oximyl hepatitis C protease inhibitors 失效
标题翻译：大蓖麻丙型肝炎蛋白酶抑制剂
公开(公告)号：US08268776B2
公开(公告)日：2012-09-18
申请号：US12016643
申请日：2008-01-18
申请人： Ying Sun , Deqiang Niu , Guoyou Xu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Deqiang Niu , Guoyou Xu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/00
CPC分类号： C07K5/0804 , C07K5/0812 , C07K7/06
摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

66. 发明授权

US08193346B2 Process for making macrocyclic oximyl hepatitis C protease inhibitors 有权
标题翻译：制备大环脯氨酰丙型肝炎蛋白酶抑制剂的方法
公开(公告)号：US08193346B2
公开(公告)日：2012-06-05
申请号：US12328380
申请日：2008-12-04
申请人： Seble Wagaw , Matthew Ravn , Kenneth Engstrom , Guoyou Xu , Zhe Wang , Ying Sun , Deqiang Niu , Yat Sun Or
发明人： Seble Wagaw , Matthew Ravn , Kenneth Engstrom , Guoyou Xu , Zhe Wang , Ying Sun , Deqiang Niu , Yat Sun Or
IPC分类号： C07K5/08 , C07K5/12
CPC分类号： C07D487/04 , C07D519/00 , C07K5/0802 , C07K5/0804 , C07K5/081
摘要： The present invention relates to a process for the preparation of macrocyclic compounds that are useful as hepatitis C virus (HCV) protease inhibitor compounds.
摘要翻译：本发明涉及可用作丙型肝炎病毒（HCV）蛋白酶抑制剂化合物的大环化合物的制备方法。

67. 发明授权

US07582605B2 Phosphorus-containing hepatitis C serine protease inhibitors 有权
标题翻译：含磷的丙型肝炎丝氨酸蛋白酶抑制剂
公开(公告)号：US07582605B2
公开(公告)日：2009-09-01
申请号：US11503407
申请日：2006-08-11
申请人： Joel D. Moore , Deqiang Niu , Guoyou Xu , Dong Liu , Yat Sun Or , Zhe Wang
发明人： Joel D. Moore , Deqiang Niu , Guoyou Xu , Dong Liu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/06 , C07K5/08
CPC分类号： A61K38/21 , C07K5/06191 , C07K5/0804 , A61K2300/00
摘要： The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I或式II的磷衍生化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

68. 发明申请

US20090191153A1 OXIMYL MACROCYCLIC DERIVATIVES 有权
标题翻译： OXIMYL MACROCYCLIC衍生物
公开(公告)号：US20090191153A1
公开(公告)日：2009-07-30
申请号：US12327453
申请日：2008-12-03
申请人： Ying Sun , Deqiang Niu , Guoyou Xu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Deqiang Niu , Guoyou Xu , Yat Sun Or , Zhe Wang
IPC分类号： A61K31/407 , C07D487/04 , A61K31/4439 , A61K31/501 , A61K31/497 , A61K31/427 , A61K31/506 , A61K31/496 , A61K31/5377 , A61K31/54 , A61K31/55 , A61P31/12 , A61K38/21 , A61K31/708
CPC分类号： C07D245/04
摘要： The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
摘要翻译：本发明涉及式I化合物或其药学上可接受的盐，酯或前体药物：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

69. 发明申请

US20090180981A1 QUINOXALINYL DERIVATIVES 有权
标题翻译：喹喔啉衍生物
公开(公告)号：US20090180981A1
公开(公告)日：2009-07-16
申请号：US12327538
申请日：2008-12-03
申请人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , C07K5/12 , A61K38/12 , A61P31/12
CPC分类号： C07D487/04 , A61K38/212 , A61K38/215 , C07K5/06165 , C07K5/0812 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
摘要翻译：本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

70. 发明申请

US20090156800A1 PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS 有权
标题翻译：制备大环氧化酶抑制剂C蛋白酶抑制剂的方法
公开(公告)号：US20090156800A1
公开(公告)日：2009-06-18
申请号：US12328380
申请日：2008-12-04
申请人： Seble Wagaw , Matthew Ravn , Kenneth Engstrom , Guoyou Xu , Zhe Wang , Ying Sun , Deqiang Niu , Yat Sun Or
发明人： Seble Wagaw , Matthew Ravn , Kenneth Engstrom , Guoyou Xu , Zhe Wang , Ying Sun , Deqiang Niu , Yat Sun Or
IPC分类号： C07D245/02
CPC分类号： C07D487/04 , C07D519/00 , C07K5/0802 , C07K5/0804 , C07K5/081
摘要： The present invention relates to a process for the preparation of macrocyclic compounds that are useful as hepatitis C virus (HCV) protease inhibitor compounds.
摘要翻译：本发明涉及可用作丙型肝炎病毒（HCV）蛋白酶抑制剂化合物的大环化合物的制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式